Current Opinion in Pharmacology

Current Opinion in Pharmacology is a review journal published by Elsevier that was established in 2001 and surveys advances in pharmacology and drug discovery, with a 2025 Journal Impact Factor of 5.5.《药理学新见》（Current Opinion in Pharmacology）由（Elsevier）出版，2001 年创办，系统梳理药理学与药物发现领域的进展，2025 年影响因子为 5.5。

Scope

• The journal publishes systematic expert reviews rather than original research, mapping the most important recent papers in each field.本刊发表系统性的专家综述而非原始研究，梳理各领域近期最重要的文献。
• Reviews are grouped into sections, including cancer, cardiovascular and respiratory pharmacology.综述按板块分组，包括肿瘤、心血管与呼吸药理学。
• Central and peripheral nervous system pharmacology, and neuropsychopharmacology, form a further section.中枢与周围神经系统药理学，以及神经精神药理学，构成另一板块。
• Infectious diseases, anti-infective therapy and immunopharmacology are covered.感染性疾病、抗感染治疗与免疫药理学均被收录。
• Gastrointestinal, renal and endocrine pharmacology, and metabolic disease, are represented.胃肠、肾脏与内分泌药理学以及代谢疾病均有收录。
• Drug discovery, including target identification, medicinal chemistry and therapeutic biologics, is treated as a core theme.药物发现，包括靶点识别、药物化学与治疗性生物制品，被视为核心主题。
• Topics such as gene therapy, cell-based therapy and novel drug delivery are given dedicated attention.基因治疗、细胞治疗与新型药物递送等主题受到专门关注。

History

• Current Opinion in Pharmacology was established in 2001 by Elsevier as part of the Current Opinion series.《药理学新见》由（Elsevier）于 2001 年创办，属（Current Opinion）系列。
• The journal is issued every two months, and each issue assembles reviews around a handful of themes.本刊每两个月出版一期，每期围绕若干主题汇编综述。
• Its early editors were Norman G. Bowery and Terry P. Kenakin, followed by David G. Trist and Francesco Di Virgilio.历任主编包括 Norman G. Bowery 与 Terry P. Kenakin，其后为 David G. Trist 与 Francesco Di Virgilio。
• Sheng-Tao Hou of the Southern University of Science and Technology took over as editor-in-chief with the February 2025 issue.南方科技大学的侯圣陶自 2025 年 2 月号起接任主编。
• The journal has a low self-citation rate and a stable impact factor, which reached 5.5 in 2025.本刊自引率较低，影响因子保持稳定，2025 年为 5.5。
• Each review is commissioned, and the journal is known for concise synthesis rather than comprehensive coverage.每篇综述均为约稿，本刊以凝练的综合而非面面俱到的覆盖见长。

Editors

• Sheng-Tao Hou, a neuroscientist at the Southern University of Science and Technology in Shenzhen, leads the journal.深圳南方科技大学的神经科学家侯圣陶主持本刊。
• A senior editorial advisory board covers each thematic section, and the board of about 28 members spans twelve countries.高级编辑顾问委员会覆盖各主题板块，编委会约 28 位成员分布于十二个国家。
• Manuscripts are peer reviewed, and reviews are invited from recognised authorities in each field.稿件经同行评审，综述向各领域公认的权威学者约稿。
• The journal supports open access publication, so authors may pay to make individual articles free to read.本刊支持开放获取发表，作者可付费使单篇论文免费阅读。
• The journal does not accept unsolicited primary research papers, only reviews and themed collections.本刊不接受未经约稿的原始研究论文，只接收综述与主题合集。
• Special sections on cancer and other themes are edited by guest editors, who write the section introduction.肿瘤及其他主题的专章由客座编辑主持，并由其撰写该章导言。